CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

Chongqing Zhifei Biological Products Co., Ltd.

300122

CNE100000V20

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
34.83 ^CNY	+1.81%		-13.98%	-43.00%

Apr. 23	Chongqing Zhifei Biological Products' 2023 Profit Rises 7%; Shares Plunge 12%	MT
Apr. 22	Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Chongqing Zhifei Biological Products Co., Ltd. announces an Equity Buyback for CNY 500 million worth of its shares.

February 22, 2024 at 05:59 am EST

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) announces a share repurchase program. Under the program, the company will repurchase up to CNY 500 million worth of its shares. The repurchase program is valid for 12 months.

Latest news about Chongqing Zhifei Biological Products Co., Ltd.

Chongqing Zhifei Biological Products' 2023 Profit Rises 7%; Shares Plunge 12%	Apr. 23	MT
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Tranche Update on Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback Plan announced on February 22, 2024.	Mar. 28	CI
Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback announced on February 22, 2024, has closed with 6,210,253 shares, for CNY 300.01 million.	Mar. 27	CI
Chongqing Zhifei Biological Products Co., Ltd. announces an Equity Buyback for CNY 500 million worth of its shares.	Feb. 22	CI
Chongqing Zhifei Biological Products Co., Ltd. authorizes a Buyback Plan.	Feb. 21	CI
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China	Jan. 10	MT
Zhifei Biological Products to Acquire Local Biopharma Firm, Expanding Into Metabolic Disease Treatments	Nov. 27	MT
Chongqing Zhifei Biological Products Co., Ltd. signed a letter of intent to acquire Shanghai Polaris Biology Co., Ltd.	Nov. 22	CI
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Middle East Conflict Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Monday	23-10-09	MT
GSK Signs Distribution Deal With China's Zhifei for Shingles Vaccine	23-10-09	MT
Chongqing Zhifei Biological Enters Exclusive Distribution Deal With GSK	23-10-09	MT
Trending : GSK Signs $3 Billion Shingles Vaccine Deal in China	23-10-09	DJ
GSK Strikes $3.06 Billion Shingles Vaccine Deal With China's Zhifei -- Update	23-10-09	DJ
European Midday Briefing : Oil Surges, Stocks Fall on Middle East Conflict	23-10-09	DJ
GSK inks agreement with Zhifei to promote shingles vaccine	23-10-09	AN
GSK Secures GBP2.5 Billion Partnership for Shingles Vaccine in China	23-10-09	MT
GSK signs shingles vaccine deal with China's Zhifei for about $3 bln	23-10-09	RE
Metro Bank secures deal to shore up finances	23-10-09	AN
GSK Partners With Zhifei to Boost Shingles Vaccine Availability in China	23-10-09	DJ
GSK signs shingles vaccine deal with China's Zhifei for about $3 bln	23-10-09	RE
GSK plc and Zhifei Announce Exclusive Strategic Vaccine Partnership in China	23-10-09	CI
Zhifei Biological Products’ H1 Profit Rises 14% as Revenue Jumps 33%	23-08-29	MT
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI

Chart Chongqing Zhifei Biological Products Co., Ltd.

Duration

Period

Chart Chongqing Zhifei Biological Products Co., Ltd.

More charts

Company Profile

Chongqing Zhifei Biological Products Co., Ltd. specializes in the research and development of vaccines for human use. The products include, in particular, bacterial vaccines for the prevention of meningitis, tuberculosis, rabies and influenza.

Sector

Pharmaceuticals

Calendar

2024-06-17 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Chongqing Zhifei Biological Products Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.83 CNY

Average target price

62.47 CNY

Spread / Average Target

+79.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B
INTRA-CELLULAR THERAPIES, INC.	+2.29%	7.72B

Biopharmaceuticals